Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.17 (
CaMKII
)
4,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We present here the identification and characterization of an
SCP3
(small C-terminal domain phosphatase-3) homologue in smooth muscle and show, for the first time, that it dephosphorylates
CaMKII
[Ca(2+)/CaM (calmodulin)-dependent protein kinase II].
SCP3
is a PP2C (protein phosphatase 2C)-type phosphatase that is primarily expressed in vascular smooth muscle tissues and specifically binds to the association domain of the CaMKIIgamma G-2 variant. The dephosphorylation is site-specific, excluding the Thr(287) associated with Ca(2+)/CaM-independent activation of the kinase. As a result, the autonomous activity of CaMKIIgamma G-2 is not affected by the phosphatase activity of
SCP3
.
SCP3
co-localizes with CaMKIIgamma G-2 on cytoskeletal filaments, but is excluded from the nucleus in differentiated vascular smooth muscle cells. Upon depolarization-induced Ca(2+) influx, CaMKIIgamma G-2 is activated and dissociates from
SCP3
. Subsequently, CaMKIIgamma G-2 is targeted to cortical adhesion plaques. We show here that
SCP3
regulates phosphorylation sites in the catalytic domain, but not those involved in regulation of kinase activation. This selective dephosphorylation by
SCP3
creates a constitutively active kinase that can then be differentially regulated by other phosphorylation-dependent regulatory mechanisms.
...
PMID:Regulation of Ca2+/calmodulin kinase II by a small C-terminal domain phosphatase. 1833 82